ACTRN12608000167369已完成不适用
A randomised, double-blind, parallel group, placebo-controlled study investigating the efficacy and tolerability of adjuvant nebulised magnesium therapy in conjunction with standard emergency department treatment of acute severe exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 36 Years 至 o limit（—）
- 性别
- All
入选标准
- •Aged greater than 35 years old; Doctor diagnosis of COPD, emphysema or chronic bronchitis; Presentation to the Emergency Department (ED) with a severe exacerbation of COPD (initial FEV1 < or = 50% predicted)
排除标准
- •Patients requiring intubation or non-invasive ventilation on arrival, or too unwell to perform spirometry at presentation; Another serious medical condition that would prevent their participation in the trial; Pregnant women; Pneumothorax
研究者
相似试验
进行中（未招募）
1 期
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.Adjuvant breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003839-30-DEAstraZeneca AB1,800
已完成
3 期
A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.Breastcancer10006232NL-OMON47654Astra Zeneca40
进行中（未招募）
不适用
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.Adjuvant breast cancerMedDRA version: 17.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003839-30-ESAstraZeneca AB1,320
进行中（未招募）
Unknown
A randomised, double-blind, parallel group, placebo controlled, trial of Bactek for the prevention of lower respiratory tract infections in preterm infantsRespiratory outcomes after premature birth including lower respiratory tract infections and wheeze.RespiratoryISRCTN14019493Cardiff University542
进行中（未招募）
1 期
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.Adjuvant breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003839-30-NLAstraZeneca AB1,800